Relationship between immune-related adverse events and the long-term outcomes in recurrent/metastatic head and neck squamous cell carcinoma treated with nivolumab

•Nivolumab, which is one of an immune checkpoint inhibitor (ICIs), has been shown to be effective for the treatment of recurrent/metastatic head and neck squamous cell carcinoma(R/MHNSCC).•In some cancers, ICIs have induced immune-related adverse events (irAEs), and irAEs have been shown to be assoc...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Oral oncology 2020-02, Vol.101, p.104525-104525, Article 104525
Hauptverfasser:	Matsuo, Mioko, Yasumatsu, Ryuji, Masuda, Muneyuki, Toh, Satoshi, Wakasaki, Takahiro, Hashimoto, Kazuki, Taura, Masahiko, Uchi, Ryutaro, Nakagawa, Takashi
Format:	Artikel
Sprache:	eng
Schlagworte:	Head and neck squamous cell carcinoma Immune-related adverse events Nivolumab
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!